Biotechnology innovator Hanchor Bio-KY (漢康生技; 6995 TW) convened its Annual General Shareholders' Meeting. Chairman and CEO Dr. Scott Liu highlighted that the current fiscal year marks a critical inflection point for the company as it transitions from a "clinical Proof-of-Concept (POC)" model into full "commercial and capital market value realization." The organization is concentrating its capital and operational resources on advancing high-value oncology assets with strong out-licensing monetization potential, including its core candidates: HCB101, HCB301, HCB303, and HCB206.

• Financial Retrospective: In the 2025 financial year, Hanchor Bio recognized its initial upfront milestone payments from the out-licensing of its lead asset, HCB101. This transaction drove annual revenue to NT$312 million, significantly narrowing net losses and bringing its loss per share down to NT$2.26.
• Clinical Milestones & Pipeline Framework:
• HCB101: The lead oncology asset is on track to achieve Phase 2a clinical Proof-of-Concept (POC) data readouts across three distinct indications. Concurrently, its clinical trial for second-line gastric cancer is scheduled to finalize Phase 2a patient enrollment this year.
• Preclinical to IND Ramping: Hanchor Bio plans to advance three pipeline projects through IND-enabling preclinical evaluation and formal regulatory filings.
• IND Applications: The company is executing regulatory tracks to submit two Investigational New Drug (IND) applications, with at least one project structurally oriented toward global clinical markets to align regulatory strategy with international business development targets.
• Platform Moats: Hanchor Bio will continue to expand therapeutic indications to secure early clinical POC readouts while widening the competitive gap of its proprietary FC-based Bi-functional & Di-functional Biologics (FBDB™) platform, which serves as the core accelerator for its oncology and autoimmune disease discovery engines. Over the next 12 to 24 months, management will remain heavily focused on elevating the international co-development and licensing value of these core assets.

Resource: 漢康今年邁向商業與資本市場價值兌現 聚焦高授權潛力新藥